John Vandermosten

- Intelligent Bio Solutions Inc. (INBS) announced the addition of **33 new customer accounts** during its fiscal first quarter, which ended **September 30, 2025**.  **[1725430_0001493152-25-020262_ex99-1.htm:0]** 
- This represents a **50% increase** in new customer accounts compared to the same period in the prior year, bringing the total active accounts to over **480**.  **[1725430_0001493152-25-020262_ex99-1.htm:0]** 
- Growth was particularly strong in the **United Kingdom** and across sectors including maritime, transportation and logistics, electrical and electronic manufacturing, construction, and the newly entered government administration sector.  **[1725430_0001493152-25-020262_ex99-1.htm:0]** 
- Approximately **91%** of these new accounts were first-time adopters of INBS's drug screening solution.  **[1725430_0001493152-25-020262_ex99-1.htm:0]**

Intelligent Bio Solutions Inc. Secures 33 New Customer Accounts in Q1 Fiscal 2026

- On **October 16, 2025**, Intelligent Bio Solutions Inc. stockholders approved an amendment to the **2019 Long Term Incentive Plan**, increasing the aggregate number of shares available for issuance by an additional **495,000 shares**, from **1,300,000 shares to 1,795,000 shares**  **[1725430_0001493152-25-018806_form8-k.htm:1]** ,.  **[1725430_0001493152-25-018806_form8-k.htm:2]** 
- Stockholders also approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a **reverse stock split** at a ratio of not less than 1-for-2 and not greater than 1-for-10, if the Board determines it advisable to regain compliance with Nasdaq minimum bid price requirements.  **[1725430_0001493152-25-018806_form8-k.htm:2]** 
- Other proposals approved at the Annual Meeting included the election of four directors, the ratification of UHY LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, and the issuance of up to **4,147,616 shares** of common stock upon the exercise of warrants.  **[1725430_0001493152-25-018806_form8-k.htm:2]**

Intelligent Bio Solutions Inc. Stockholders Approve Incentive Plan Amendment and Reverse Stock Split Proposal

- Intelligent Bio Solutions Inc. (INBS) has provided an updated timeline for the anticipated **FDA 510(k) clearance** for its Intelligent Fingerprinting Drug Screening System for opiate codeine.  **[1725430_0001493152-25-015068_ex99-1.htm:0]** 
- The company plans to commence **clinical studies** to gather additional supporting data, with these studies scheduled to conclude in the **first half of 2026**.  **[1725430_0001493152-25-015068_ex99-1.htm:0]** 
- INBS anticipates receiving FDA 510(k) clearance in the **second half of 2026**.  **[1725430_0001493152-25-015068_ex99-1.htm:0]** 
- The Intelligent Fingerprinting Drug Screening System is currently adopted by **over 450 accounts in 24 countries** and has 18 distribution partners, with ongoing commercial operations outside the U.S..  **[1725430_0001493152-25-015068_ex99-1.htm:0]**

Intelligent Bio Solutions Updates FDA 510(k) Clearance Timeline

- Intelligent Bio Solutions Inc. (INBS) announced on **September 17, 2025**, that the FDA requires the company to **resubmit a new 510(k) notification** for its Intelligent Fingerprinting Drug Screening System.  **[1725430_0001493152-25-013836_ex99-1.htm:0]** **[1725430_0001493152-25-013836_form8-k.htm:1]** 
- This decision follows INBS's initial submission in **December 2024** and a response to an FDA Additional Information request in **August 2025**.  **[1725430_0001493152-25-013836_ex99-1.htm:0]** 
- The FDA's request for a new submission is due to the device being a **first-of-its-kind sweat-based product** with no comparable cleared or approved alternatives on the market.  **[1725430_0001493152-25-013836_ex99-1.htm:0]** 
- INBS expects to provide an investor update with an **updated timeline for FDA clearance within the next ten days**.  **[1725430_0001493152-25-013836_ex99-1.htm:0]** **[1725430_0001493152-25-013836_form8-k.htm:1]**

INTELLIGENT BIO SOLUTIONS (INBS)